The growth inhibitory effects of anti-HER2 treatment in IHC 2+ breast cancer cell lines were assessed via cell viability and compared to anti-HER2 treatments in IHC 3 + SK-BR-3 and BT474 cells (Fig. S1C). Here, ERBB2 is linked to breast cancer.